Risk analysis for PAH was based on the abbreviated version of the risk stratification strategy formulated by ESC/ERS in 2015, which includes the evaluation of WHO functional classification, 6 min walk distance, NT-proBNP level or right atrial pressure, and cardiac index/venous oxygen saturation. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.